ClinicalTrials.gg
Enrolling by invitationNCT07475611Updated Mar 16, 2026

Effectiveness of an Interactive Screen in the Rehabilitation of Neglect in Adults With Subacute Stroke: A Randomized Controlled Trial in Argentina.

An interventional study of Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect and occupational therapy conventional treatment in Stroke and Neglect, Hemispatial, sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Enrolling by invitation at 1 site in Argentina. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2025, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Stroke with a site in Argentina — 9 open to participants now, 12 under way, 3 of them phase 3. Stroke · Argentina.

Planned enrollment
36th of 37
12 · median 5,390
Started
2025
with 3 others
No phase
7 of 50
4 open now
Primary completion
2026-12
later than 0 of 11 live
Registered
48th of 50
by date
Lead sponsor
3 of 50
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia

Among the 50 studies in Stroke with a site in Argentina, this one is the 36th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 48th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 50 studies in Stroke with a site in Argentina are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Stroke with a site in Argentina, or all of them as a file.
02

Study summary

Hemispatial neglect is one of the most frequent and disabling sequelae after a stroke, particularly following right-hemisphere lesions. Its prevalence ranges from 25% to 80% and is associated with poorer functional outcomes, increased risk of falls, prolonged hospital stays, and lower rates of discharge to home. In response to these challenges, rehabilitation technologies have emerged as promising tools, especially during the subacute phase of stroke, a critical period for neuroplasticity. The MYRO® device-an adjustable interactive screen that enables intensive, task-oriented training-has shown benefits in promoting visual scanning, midline crossing, and sensorimotor integration through personalized exercises with constant feedback.

This study aims to evaluate the effectiveness of MYRO® combined with conventional occupational therapy in patients with left hemispatial neglect secondary to subacute stroke. A randomized clinical trial will be conducted with 30 participants assigned to two groups: conventional occupational therapy (OT-C) and occupational therapy plus rehabilitation technology using MYRO® (OT-M). Both groups will receive interventions for four weeks, with assessments at baseline, at the end of the protocol, and at a six-week follow-up. Outcome measures will include the NIHSS, FIM, Catherine Bergego Scale, Cancelation Bells Test, and Line Bisection Test.

It is expected that the use of MYRO® will enhance visuospatial attention toward the left hemifield and accelerate functional recovery compared with conventional treatment alone. The results could provide relevant evidence supporting the integration of interactive technology into neurofunctional rehabilitation within the Argentine context.

03

Conditions studied

  • Stroke
  • Neglect, Hemispatial

Keywords

  • neglect
  • stroke
  • rehabilitation
  • virtual reality
04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right-sided stroke. Ischemic or hemorrhagic.
  • Currently in the subacute phase of recovery from the event (1 week to \<6 months post-stroke).
  • Presence of left hemineglect as determined by the Catherine Bergego Scale and/or Cancel Bells Test and/or Line Bisection Test.
  • Age 18 to 88 years.
  • Native Spanish speaker.

Exclusion criteria

Exclusion Criteria:

  • Bilateral stroke. Previous strokes.
  • Medically unstable condition.
  • Previous visual impairments that prevent interaction with the device screen.
  • Presence of severe left homonymous hemianopsia. Determined by the total absence of vision in the entire left visual field, evaluated by confrontation visual field testing during the neurological physical examination.
  • Severe aphasia that prevents the comprehension of simple instructions that guarantee the completion of the task, determined by an NIHSS scale with a score of 3 points on the aphasia subitem.
  • Severe attentional and executive function deficits that prevent the comprehension of simple instructions, determined by the Catherine Bergego Scale and/or Cancel Bells Test and/or Line Bisection Test.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Other
    Neglect Conventional intervenction

    Conventional occupational therapy intervention for the treatment of neglect

    Other: occupational therapy conventional treatment

  • Experimental
    Neglect Virtual Intervention

    Use of an interactive screen for neglect rehabilitation

    Device: Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect

Interventions

  • DeviceMyro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect

    Use of the Myro Interactive Screen (Tyromotion) as a tool for occupational therapy approach in patients with unilateral neglect

  • Otheroccupational therapy conventional treatment

    Bottom - up, restorative occupational therapy approach to unilateral neglect

06

What researchers measure

Primary outcomes

  1. Catherine Bergego Scale for Neglect

    The Catherine Bergego Scale (CBS) is a functional assessment composed of 10 items, each scored on a 0-3 scale, resulting in a total score ranging from 0 to 30. A score of 0 indicates the absence of neglect, whereas a score of 30 reflects severe unilateral neglect. Higher total scores represent worse performance and greater severity of neglect, while lower scores indicate better functional outcomes. Severity levels are commonly categorized as follows: 1-10 points indicate mild behavioral neglect, 10-20 indicate moderate neglect, and 21-30 represent severe behavioral neglect.

    Time frame: from the start of treatment until 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Williams LJ, Kernot J, Hillier SL, Loetscher T. Spatial Neglect Subtypes, Definitions and Assessment Tools: A Scoping Review. Front Neurol. 2021 Nov 24;12:742365. doi: 10.3389/fneur.2021.742365. eCollection 2021. PubMed 34899565 ↗
  • Williams LJ, Loetscher T, Hillier S, Hreha K, Jones J, Bowen A, Kernot J. Identifying spatial neglect - an updated systematic review of the psychometric properties of assessment tools in adults post-stroke. Neuropsychol Rehabil. 2025 Apr;35(3):628-667. doi: 10.1080/09602011.2024.2346212. Epub 2024 May 10. PubMed 38727637 ↗

Individual participant data

Plan to share: Undecided — Only IPDs used for the publication of the results will be included.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 14 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 16, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
May 1, 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475611
Lead sponsor
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Responsible party
Vanina Lado (Occupational Therapy Coordinator, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia) — Principal investigator
First posted
Mar 16, 2026
Start date
Oct 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Vanina Lado
study director · Fundacion para la Lucha de las Enfermedades Neurologicas de la Infancia, Sede Escobar

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion